Last reviewed · How we verify
Preemptive Analgesia Of Dexmedetomidine
Preemptive Analgesia Of Dexmedetomidine is a Alpha-2 adrenergic agonist Small molecule drug developed by China International Neuroscience Institution. It is currently FDA-approved for Preemptive analgesia to reduce postoperative pain, Perioperative sedation and analgesia.
Dexmedetomidine is a selective alpha-2 adrenergic agonist that reduces pain perception and provides analgesia through central nervous system effects.
Dexmedetomidine is a selective alpha-2 adrenergic agonist that reduces pain perception and provides analgesia through central nervous system effects. Used for Preemptive analgesia to reduce postoperative pain, Perioperative sedation and analgesia.
At a glance
| Generic name | Preemptive Analgesia Of Dexmedetomidine |
|---|---|
| Sponsor | China International Neuroscience Institution |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Pain Management |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds to alpha-2 adrenergic receptors in the central nervous system, particularly in the spinal cord and brainstem, which inhibits the release of norepinephrine and reduces pain signal transmission. When used preemptively (before surgical stimulation), it prevents the establishment of central sensitization and reduces postoperative pain requirements. This mechanism provides both analgesic and sedative effects, making it useful in perioperative pain management.
Approved indications
- Preemptive analgesia to reduce postoperative pain
- Perioperative sedation and analgesia
Common side effects
- Hypotension
- Bradycardia
- Dry mouth
- Sedation
Key clinical trials
- Analgesic Effect of Infraspinatus-teres Minor Block for Pre-emptive Analgesia in Patients Undergoing Shoulder Surgeries. (NA)
- Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG (PHASE4)
- Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain (PHASE4)
- Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair (PHASE4)
- Opioid Free Anesthesia on the Quality of Early Recovery (NA)
- Transverse Abdominal Block for Analgesia in Casarean Section (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preemptive Analgesia Of Dexmedetomidine CI brief — competitive landscape report
- Preemptive Analgesia Of Dexmedetomidine updates RSS · CI watch RSS
- China International Neuroscience Institution portfolio CI
Frequently asked questions about Preemptive Analgesia Of Dexmedetomidine
What is Preemptive Analgesia Of Dexmedetomidine?
How does Preemptive Analgesia Of Dexmedetomidine work?
What is Preemptive Analgesia Of Dexmedetomidine used for?
Who makes Preemptive Analgesia Of Dexmedetomidine?
What drug class is Preemptive Analgesia Of Dexmedetomidine in?
What development phase is Preemptive Analgesia Of Dexmedetomidine in?
What are the side effects of Preemptive Analgesia Of Dexmedetomidine?
What does Preemptive Analgesia Of Dexmedetomidine target?
Related
- Drug class: All Alpha-2 adrenergic agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: China International Neuroscience Institution — full pipeline
- Therapeutic area: All drugs in Anesthesia and Pain Management
- Indication: Drugs for Preemptive analgesia to reduce postoperative pain
- Indication: Drugs for Perioperative sedation and analgesia
- Compare: Preemptive Analgesia Of Dexmedetomidine vs similar drugs
- Pricing: Preemptive Analgesia Of Dexmedetomidine cost, discount & access